 |
|
|
|
 |
A Phase II Study of Bendamustine HCl in Relapsed and Primary Refractory Hodgkin's Lymphoma
[Protocol 08-041]
- Full Title :
- A PHASE II STUDY OF BENDAMUSTINE HCL IN RELAPSED AND PRIMARY REFRACTORY HODGKIN LYMPHOMA
- Purpose :
The standard treatment for patients with Hodgkin's lymphoma (HL) that has not responded to treatment or has come back after treatment is a stem cell transplant. When patients are not eligible for a transplant or when HL comes back after a transplant, there are no standard treatment options. These patients can receive chemotherapy or participate in clinical trials of novel therapies.
Bendamustine HCl is a chemotherapy agent that is effective for treating patients with various diseases, including non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. It was recently approved for the treatment of chronic lymphocytic leukemia. In addition, small studies from Eastern Europe have shown that bendamustine HCl is likely to be effective for treating HL. This study will determine the effectiveness of bendamustine HCl for treating patients with HL that has not responded to or has come back after treatment and who are not candidates for stem cell transplantation.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of HL that has persisted or returned despite prior treatment.
- Patients may not be candidates for stem cell transplantation.
- At least 4 weeks must have passed since completion of previous therapy and the start of bendamustine treatment.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Craig Moskowitz at 212-639-2696.
|
|
|
|
|
